The NIDDK Disorders of Gastrointestinal Interoception Consortium Clinical Centers (DGIC)
ID: 360625Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360625
Timeline
    Description

    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "The NIDDK Disorders of Gastrointestinal Interoception Consortium Clinical Centers (DGIC)." This initiative aims to expand the work of the NIDDK Gastroparesis Consortium by establishing a consortium that includes up to six Clinical Research Centers and a Scientific Data Research Center, focusing on disorders of gastrointestinal interoception and their underlying mechanisms. The program is critical for advancing understanding of gastrointestinal motility disorders and developing novel therapeutic targets, with an estimated total funding of $3 million and an expected six awards. Interested applicants can reach out to Dr. Terez Shea-Donohue at terez.shea-donohue@nih.gov or by phone at 301-825-2314, with proposals due by November 1, 2026, and project start dates anticipated for July 1, 2027.

    Point(s) of Contact
    Terez Shea-Donohue, Ph.D.
    (301) 825-2314
    terez.shea-donohue@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    The NIDDK Disorders of Gastrointestinal Interoception Consortium Clinical Centers (DGIC)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "The NIDDK Disorders of Gastrointestinal Interoception Consortium Clinical Centers (DGIC)." This initiative aims to expand upon the work of the NIDDK Gastroparesis Consortium by establishing a consortium that will include up to six Clinical Research Centers and a Scientific Data Research Center, focusing on disorders of gastrointestinal interoception and their associated symptoms. The program seeks to enhance understanding of gastrointestinal motility disorders, identify biomarkers for treatment efficacy, and leverage advanced technologies for future clinical trials. The estimated total program funding is $1.5 million, with one award expected. Interested applicants can contact Dr. Terez Shea-Donohue at terez.shea-donohue@nih.gov or by phone at 301-825-2314. Key deadlines include an estimated synopsis close date of November 1, 2026, and an estimated award date of July 1, 2027.
    The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers," aimed at advancing research in inflammatory bowel disease (IBD). This initiative seeks to establish up to seven Genomic Research Centers that will leverage patient cohorts, biospecimens, and data science to explore genetic, clinical, and environmental factors influencing IBD, with the goal of developing new predictors for disease outcomes and enhancing precision medicine for patients. The total estimated funding for this program is $6.4 million, with nine awards expected to be granted, and interested applicants can reach out to Dr. Ludmila Pawlikowska at ludmila.pawlikowska@nih.gov or by phone at 301-480-9372 for further information. Key deadlines include an estimated synopsis post date of August 1, 2026, and a close date of November 1, 2026, with project start anticipated on July 1, 2027.
    The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Data Coordinating Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity for the establishment of the Data Coordinating Center (DCC) for the NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC). The DCC will play a crucial role in coordinating collaborations among genetic research centers, managing participant enrollment, biospecimen collections, and overseeing data submission to central databases, all aimed at advancing research in inflammatory bowel disease (IBD). This initiative is vital for improving medical management and precision medicine for IBD patients, as it seeks to develop new predictors of disease outcomes through the integration of genetic, clinical, and environmental data. The estimated total funding for this program is $1,600,000, with one award expected to be made. Interested applicants can reach out to Dr. Ludmila Pawlikowska at Ludmila.pawlikowska@nih.gov or by phone at 301-480-9372 for further information. The application period is open until November 1, 2026, with an anticipated award date of July 1, 2027.
    Silvio O. Conte Digestive Diseases Research Core Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs) grant program, aimed at enhancing research collaboration in digestive and liver diseases. Eligible applicants must demonstrate a strong ongoing research base with at least $3 million in direct costs per year, including a minimum of 30% funding from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and must focus on a central theme relevant to the NIDDK's mission. This program is crucial for fostering productivity and innovation among researchers, with an expected four awards to be made, and applications are due by July 27, 2026. For further inquiries, interested parties can contact Dr. Katrina J. Serrano at katrina.serrano@nih.gov or by phone at 301-480-7855.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)." This initiative aims to support high-risk, investigator-initiated, multi-center clinical studies by facilitating early peer review and the development of essential operational documents necessary for conducting the proposed studies. The program emphasizes the importance of addressing diseases affecting underrepresented populations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) in their submissions. The maximum award amount is $225,000 per year for up to two years, with applications opening on May 9, 2025, and a submission deadline of June 10, 2027. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Impact, Interdisciplinary Science in NIDDK Research Areas" (PAR-25-277) aimed at supporting innovative research that addresses critical knowledge gaps in diabetes, digestive, and kidney diseases. This grant program encourages interdisciplinary approaches to foster discovery-based science and develop transformative technologies that can significantly impact the broader scientific community. Eligible applicants include a wide range of organizations, such as higher education institutions and nonprofits, with proposals accepted for projects lasting up to five years. Interested parties should ensure compliance with application guidelines and submit their proposals by the deadline of October 15, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-277.html.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk, multi-center observational studies related to diabetes, digestive, kidney, and associated diseases. This funding opportunity emphasizes hypothesis-driven research that engages diverse populations, particularly underserved communities, and requires a comprehensive study design, community engagement, and a detailed budget. The initiative is crucial for advancing health equity and enhancing participant diversity in clinical research. Interested applicants should note that the submission period opens on January 3, 2025, with a closing date of November 5, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.